BIO Comments on FDA Draft Guidance on CMC Postapproval Manufacturing Changes for Specified Biological Products
October 10, 2017
BIO submitted comments on the Food and Drug Administration’s (FDA) draft guidance, Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes for Specified Biological Products to Be Documented in Annual Reports.
BIO appreciates the effort to categorize listed annual reportable changes for biologics based on the associated commensurate risk, along with the annual reportable manufacturing type examples in the draft guidance.
However, BIO recommends the final guidance include examples of situations where annual reportable listed changes may be better categorized by applicants as a supplement based on certain specific circumstances. BIO asks for additional clarifications to the draft guidance, including whether this draft guidance will be aligned with the final ICH Q12 guideline.
Download Full Comments Below
2017-10-10 BIO Comments On CMC Postapproval In Annual Reports FINAL
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
BIO submitted comments on the Food and Drug Administration’s (FDA) draft guidance, Chemistry, Manufacturing, and Controls Postapproval Manufacturing Changes for Specified Biological Products to Be Documented in Annual Reports.
BIO appreciates the effort to categorize listed annual reportable changes for biologics based on the associated commensurate risk, along with the annual reportable manufacturing type examples in the draft guidance.
However, BIO recommends the final guidance include examples of situations where annual reportable listed changes may be better categorized by applicants as a supplement based on certain specific circumstances. BIO asks for additional clarifications to the draft guidance, including whether this draft guidance will be aligned with the final ICH Q12 guideline.